Clinically predictive preclinical efficacy testing services at your disposal
News
October 15, 2020
This week on Thursday October 15th our oncology experts will virtually travel and attend the 3rd Annual Advances in Immuno-Oncology USA Congress.
The Congress includes over 300 attendees with more than 40 presentations and case studies focussed on the latest innovations in Immuno-Oncology therapy development, patient stratification and clinical research.
Don’t miss our presentation by Dr. Mari Suominen “Preclinical evaluation of IO Therapy Response in Bone Metastases” on October 15th at 11am PDT.
Pharmatest representatives will also host two roundtable discussions. On the first day of the meeting R&D Director Jenni Mäki-Jouppila will discuss about the topic “In vitro assays for studying the effects on tumor microenvironment” and on the second day of the meeting Research Director Mari Suominen will be moderating a roundtable discussion about “Experiences of Using CD34+ Humanized Mice”.
Please also visit our virtual booth to discuss about your oncology research!
Pharmatest’s agenda during the meeting:
October 15th
9:00am PDT
Live Booth Meeting: "Meet Pharmatest Services" by Jukka Rissanen, PhD, CEO
10am PDT
Roundtable Discussion Titled: "In vitro assays for studying the effects on tumor microenvironment" by Jenni Mäki-Jouppila, PhD, R&D Director
11am PDT
Solution Provider Presentation: Evaluating IO Therapy Response In Bone Metastases by Mari Suominen, PhD, Research Director
12:00PDT
Live Booth Meeting: Q&A for poster "T Cell Killing Assay for Analyzing the Effects of Immunotherapies In Vitro" by Jenni Mäki-Jouppila, PhD, R&D Director
October 16th
9am PDT
Roundtable Discussion: "Experiences of Using CD34+ Humanized Mice" by Mari Suominen, PhD, Research Director
10am PDT
Live Booth Meeting: "Meet Pharmatest Services - Why to study bone in the context of immuno-oncology" by Jenni Mäki-Jouppila, PhD, R&D Director
September 10, 2020
Pharmatest will be taking part of the virtual ASBMR 2020 Meeting starting on Friday, September 11. We are excited about this year’s scientific program packed with cutting-edge research in the bone, mineral and musculoskeletal field.
Explore our this year’s posters showcasing our research studies:
Syngeneic Murine Bladder Cancer Growing in Bone Responds to Anti-PD-1 Treatment by Dr. Mari Suominen (P-172)
Chondrogenic Differentiation of Mesenchymal Stem Cell-Like KS483 Cells by Dr. Katja Fagerlund (P-192)
Zoledronate Treatment Improves Trabecular Bone without Affecting Bone Biomechanical Properties in + G610C Mouse Model of Osteogenesis Imperfecta by Dr. Jukka Morko (P-844)
Be sure to visit our virtual booth and connect with our experts. We will be available to answer any of your questions during the entire meeting.
Our dedicated booth hours during the meeting are
Friday 11.9. 2PM-3PM EDT and 4PM-5PM EDT
Saturday 12.9. 2PM-3PM EDT and 4PM-5PM EDT
Sunday 13.9. 10AM-11AM EDT and 2PM-3PM EDT
Monday 14.9. 10AM-11AM EDT and 2PM-3PM EDT
June 16, 2020
Pharmatest is very excited to participate in AACR virtual meeting II on June 22-24. Registration for this year’s Meeting is free!
Please meet our Team attending AACR 2020 and ready to answer any of your questions regarding our services. Unfortunately, we won't be able to meet you in person but please contact us to arrange a virtual discussion with our experts in oncology.
The following presentations will be available on AACR’s platform on June 22:
Poster 5026: Efficacy of anti-PD-1, IDO inhibitor, chemotherapy and bone-targeting agent on tumor growth in a syngeneic bone metastasis model of triple-negative breast cancer presented by Mari Suominen
Poster 2759: Immune cell killing assay for analyzing the effects of immunomodulating agents in vitro by Jenni Mäki-Jouppila
Poster 1634: Orthotopic and bone metastasis prostate cancer models using the 22Rv1 cell line by Justyna Zdrojewska
MEET OUR PRESENTERS:
Mari Suominen, PhD, Research Director
Mari Suominen joined Pharmatest in 2005. As a Study Director, she is in of charge of customer projects and new model development projects of the cancer field. Previously, she has worked at bone biology department at Schering (currently Bayer), where her responsibility was setting up new models of cancer and skeletal diseases. In her Ph.D. work she studied various therapeutic approaches in experimental mouse models of breast and prostate cancer bone metastasis, including radium-223 (Xofigo). Her whole career has focused on the interaction of bone microenvironment and cancer, and particularly on the development of new therapeutics to treat skeletal metastases.
Jenni Mäki-Jouppila, PhD, R&D Director
Jenni Mäki-Jouppila joined Pharmatest in 2016 and is working as a Research Director and R&D Director. She has a background in cell and molecular biology. She has graduated as a MSc from the Department of Biology and defended her PhD thesis from the Department of Pharmacology, Drug Development and Therapeutics in the University of Turku. Her previous work has included screening and validation of small molecular compounds and microRNAs targeting mitosis and cell division of cancer cells. Moreover, she has worked in research projects concerning hormonal regulation.
Justyna Zdrojewska, PhD, Research Director
Justyna Zdrojewska joined Pharmatest in 2017. As a Research Director she is responsible for customer projects and new product development in the field of cancer models. She graduated as MSc from Intercollegiate Faculty of Biotechnology at Gdansk University and further continued her education at Åbo Akademi University, from where she obtained her PhD degree in Cell Biology at the Department of Biosciences. Her previous work focused on protein interaction and cell migration.
Find our more about our services in oncology here.
April 30, 2020
In severe cases of SARS-CoV-2 infections, the immune system has been hyper-activated, triggering a cytokine release storm (CRS). CRS is body’s excessive immunological response against infection that may ultimately lead to organ failure. Cytokine storms are a common complication of Covid-19 and can also occur after cancer immunotherapy treatment.
When an individual gets infected by SARS-CoV-2, their immune system starts producing antibodies against viral antigens. Therefore, SARS-CoV-2 infection can be detected by measuring these antibodies in the blood of an individual, possibly also after the individual has cured from the disease.
Pharmatest can measure the levels of multiple cytokines/key inflammation markers that are indicative of pathologic inflammatory response and also SARS-CoV-2 reactive IgG class antibodies from plasma and serum samples.
Mouse models for coronavirus research are available upon request.
More information on cytokine storm and cytokine markers:
The Lancet: COVID-19: consider cytokine storm syndromes and immunosuppression. https://doi.org/10.1016/ S0140-6736(20)30628-0
Nature: In the eye of the COVID-19 cytokine storm.
March 20, 2020
Pharmatest’s projects and safety during the COVID-19 outbreak
To ensure the health and safety of Pharmatest’s employees, we have adopted the following precautionary policies until further notice:
- No visitors will be allowed at Pharmatest’s offices, with the exception of essential vendors and maintenance.
- Pharmatest staff will not attend external in-person meetings or events but will participate virtually. Internal meetings are limited and recommended to be held virtually.
- All of our own events have been postponed to a later date.
- Pharmatest staff will work remotely as much as possible.
- The laboratory staff has been guided to work in alternating shifts and to pay special attention to hygiene.
Committed to ensuring the smooth continuation of customer projects
Our primary focus is the safety of our employees, the health and welfare of the animals in our care, and the ability of our customers to continue their critical research.
All project work is operating as usual, and many pre-emptive measures are in place to ensure the normal operation of our services. In case of employee illnesses, we have a deputy procedure that will be deployed in case it is needed. Project work will continue as normal even if the pandemic situation gets worse.
We are confident in continuing to provide our services despite the current uncertain situation.
If you have any questions or concerns, please email us at info@pharmatest.com.
February 12, 2020
Pharmatest Services is pleased to announce that Dr. Jukka Rissanen will join the company as the new CEO starting on March 1st, 2020. Jukka brings extensive business and multidisciplinary scientific experience to the company.
Jukka has over 20 years of experience in various challenging roles within the pharmaceutical industry and has a long history with Pharmatest being the company’s COO for many years. Most recently he has been CEO and co-founder at PreclinApps Ltd, a medical technology company focused on drug delivery technologies.
In his new position as CEO, he will focus on the strategic growth of the business and delivering real value to customers. Chairman of the Board of Pharmatest, Mika Ali-Rantala: “We are delighted that Jukka is joining the company as the new CEO. We look forward to his leadership and knowledge supporting the continued growth of Pharmatest.”
January 20, 2020
Pharmatest will start the year 2020 with several events in California, USA. The first two, oncology seminars, are part of the Biocom seminar series and they will be held in San Francisco on January 21 and in San Diego on January 28. Topics discussed during the seminars include preclinical imaging, human immune system engrafted mouse models, and their use in preclinical oncology studies.
Our oncology experts will also attend Tumor Models event organized by Hanson Wade in San Francisco on January 22 – 24. At the Tumor Models event, Dr. Mari Suominen will have a speech titled ”Importance of Microenvironment in Evaluating IO Therapy Response in Humanized Mouse Models”. In her speech Dr. Suominen will discuss the basis of osteoimmunology and the potential of targeting immune cells in bone metastasis as well as effects of microenvironment on tumor growth and efficacy of immunotherapy.
Pharmatest will also have the following scientific presentations:
“Characterization of Anti-CTLA-4 Effects on Tumor Growth and Immune Microenvironment in a Syngeneic CT26.WT Colon Carcinoma Mouse Model”
“Efficacy of Pembrolizumab and Assessment of Tumor-Infiltrating Immune Cells in Bone Metastatic Triple-Negative Breast Cancer”.
November 25, 2019
Pharmatest Services has a great pleasure to welcome Dr. Joy Wolfram, an outstanding young scientist to present her research in the field of nanomedicines. The presentation will be held at the Visitor and Innovation Center JOKI (Lemminkäisenkatu 12b, 20520 Turku, Finland) on December 12, 2019 at 14:00 - 15:45 o'clock.
The session will start with Dr. Wolfram’s presentation “Nanomedicine for cancer and beyond” followed by a Q&A session and refreshments.
In her talk Dr. Wolfram will discuss the three emerging concepts in clinical nanomedicine: optimization of nanoparticle size and shape for improved hemodynamics, modulation of innate immunity to reduce nanoparticle clearance, and use of biological nanoparticles (i.e. extracellular vesicles).
The application of nanotechnology in medicine provides new and innovative solutions to diagnose and treat disease, as nanoscale structures exhibit multifunctionality, unique electromagnetic properties, and distinct biodistribution profiles that can be exploited. Dr. Wolfram’s goal is to bring new nanomedicines with increased therapeutic efficacy and safety to the clinic.
About the speaker: Dr. Joy Wolfram is an Assistant Professor at the renowned Mayo Clinic in Florida, where she is the director of the Nanomedicine and Extracellular Vesicles Lab and leads a research group focusing on nanotechnology in cancer. She is a native of Finland and received her master's degree in biology from the University of Helsinki in Finland. She completed her Ph.D. in Nanoscience and Technology at the University of Chinese Academy of Sciences in Beijing, China.
She was selected as one of 12 internationally accomplished Finns and earned her way to the Forbes 30 under 30 in healthcare in 2018. Dr. Wolfram has also received more than 25 scientific awards from seven different countries.
Please register on Eventbrite.com (registration has closed) for a free ticket for the event to secure your attendance.
October 18, 2019
Pharmatest Services attends AACR-NCI-EORTC Conference in Boston, MA on October 26 –30 and SITC Annual Meeting 2019 in National Harbor, MD on November 7–10. In both events, Pharmatest publishes novel models and emerging scientific findings from preclinical immuno-oncology studies.
In the AACR-NCI-EORTC conference Pharmatest has the following poster presentations:
-
Establishment of a novel prostate cancer bone metastasis model in humanized mice and early efficacy results of pembrolizumab. Late-breaking poster A148 on Sunday, October 27.
- Establishment of primary tumor models of TNBC and ER+/HER2- breast cancer in humanized mice and validation of pembrolizumab efficacy. Poster B143 on Monday, October 28.
- Lack of immunotherapy efficacy in a syngeneic bone metastasis model of triple-negative breast cancer. Poster B144 on Monday, October 28.
In the SITC Annual Meeting 2019 Pharmatest has the following poster presentation:
- Pitfalls in preclinical development of immunotherapies for ER+ breast cancer: estrogen as an immunomodulator potentially influencing pembrolizumab efficacy in a breast cancer model in humanized mice. Poster P284, presented on Saturday, November 9.
Pharmatest welcomes everyone to visit our posters in the events. If you would like to schedule a meeting with our representatives during the events click here.
August 20, 2019
Shareholders of Pharmatest have elected Dr. Joy Wolfram as a new board member. Dr. Wolfram is Assistant Professor at the renowned Mayo Clinic, where she is the director of the Nanomedicine and Extracellular Vesicles Lab and leads a research group focusing on nanotechnology in cancer.
Dr. Wolfram received her master's degree in biology from the University of Helsinki in Finland and completed her Ph.D. in Nanoscience and Technology at the University of Chinese Academy of Sciences in Beijing, China. She earned her way to the Forbes 30 under 30 in healthcare in 2019 and has received more than 25 scientific awards from seven different countries.
Pharmatest offers clinically predictive preclinical efficacy services in skeletal diseases and oncology, and has special expertise in bone metastasis models. The research of Dr. Wolfram focuses on developing new treatments for metastatic breast cancer. Her research goal is to use nanotechnology to design multifunctional and targeted therapies, thereby increasing therapeutic efficacy and reducing adverse effects in patients.
Jussi Halleen, CEO of Pharmatest comments: “Dr. Wolfram’s unique set of experience and expertise and in-depth knowledge of cancer research will be extremely valuable to Pharmatest. Her innovative thinking is exactly what we are looking for and we are honored to have her join our board.”
Joy Wolfram says: “I am very excited to join the board of Pharmatest. Pharmatest’s mission to reduce the high failure rates in oncology clinical trials by novel predictive preclinical models is an ambitious but achievable goal with their highly skilled and innovative staff. I hope that my experience in oncology can help to achieve this goal especially in the field of advanced, metastatic cancer where the need for novel therapies is the highest.”
Dr. Wolfram will join Pharmatest in the ASBMR annual meeting in Orlando on September 21. She will also visit the headquarters of Pharmatest in Turku, Finland on December 12, 2019, and at the same time host an intriguing presentation about her research.
August 13, 2019
Pharmatest Services attends Annual Meeting of The American Society for Bone and Mineral Research (ASBMR) that will be held in Orlando, FL, USA on September 20 – 23, 2019. Pharmatest attends the event with a booth (#429) and has 6 scientific presentations.
Pharmatest Services is a contract research organization that offers preclinical efficacy services for the pharmaceutical industry in the fields of oncology and skeletal diseases. ASBMR Annual Meeting is the leading scientific event in the field of bone research globally.
This year Pharmatest attends ASBMR with the following six scientific presentations:
- HER2 Positive Breast Cancer Bone Metastasis Model for Studying Efficacy of Novel Therapies. Poster presentation #SAT-137 on Saturday, September 21, 2019 from 12:30 pm – 2:30 pm.
- Effect of Zoledronic Acid Treatment on Bone in +/G610C Mouse Model of Osteogenesis Imperfecta. Poster Presentation #SAT-924 on Saturday, September 21, 2019 from 12:30 pm – 2:30 pm.
- Prostate Cancer Bone Metastasis Model for Preclinical Evaluation of Radiopharmaceuticals. Poster Presentation #SUN-154 on Sunday, September 22, 2019 from 12:30 pm – 2:30 pm.
- Tartrate-Resistant Acid Phosphatase 5b in Rat Serum and Plasma. Poster presentation #SUN-849 on Sunday, September 22, 2019 from 12:30 pm – 2:30 pm.
- Syngeneic Bone Metastasis Models for Testing Efficacy of Novel Therapies. Poster presentation #MON-167 on Monday, September 23, 2019 from 12:00 pm – 2:00 pm.
- Young Adult Male and Female +/G610C Mice as an Animal Model of Osteogenesis Imperfecta. Poster Presentation #MON-945 on Monday, September 23, 2019 from 12:00 pm – 2:00 pm.
Pharmatest welcomes everyone to visit our posters and booth #429 in the event. If you would like to schedule a meeting with our representatives during the ASBMR meeting click here.
May 31, 2019
Pharmatest Services has published an invited review article about preclinical bone metastasis models and a research article about the first humanized mouse model of bone metastasis. Humanized mouse models allow confirming efficacy of novel immunotherapies in bone metastatic microenvironment.
Pharmatest Services is a CRO that offers preclinical efficacy services in the fields of oncology and skeletal diseases. In oncology Pharmatest has been the global leading expert in bone metastasis models since 2005.
Pharmatest has recently published the following two scientific papers:
- Novel and Conventional Preclinical Models to Investigate Bone Metastasis
Tiina Kähkönen, the lead author in the publications says: “In Pharmatest, we are constantly developing novel bone metastasis models. Now, for the first time, we are bringing these models to humanized mice with functional human immune system, allowing to test the efficacy of immunotherapies on bone metastases.”
Jussi Halleen, CEO of Pharmatest comments: “The majority of deaths in breast, prostate, lung, and many other cancers are caused by bone metastases, and bone microenvironment changes tumor properties and induces drug resistance. I hope that our publications will help to convince the pharmaceutical industry about the importance of confirming compound efficacy in metastasis models before entering clinical trials.”
May 10, 2019
Pharmatest attends the 4th Annual Advances in Immuno-oncology Congress arranged by Oxford Global Conferences in London on May 20 – 21, and arranges a seminar titled “Example Studies in Immunodeficient and Humanized Mouse Models and Considerations for Drug Development” in London on May 23 together with Valirx Plc.
Pharmatest Services is a CRO that offers preclinical efficacy services in the fields of oncology and skeletal diseases. In oncology Pharmatest has been the global leading expert in bone metastasis models since 2005.
In the 4th Annual Advances in Immuno-oncology Congress, Pharmatest has a booth and the following scientific presentations:
- Oral presentation “Importance Of Microenvironment In Evaluating IO Therapy Response– Case Examples From Bone Metastasis Models In Humanized Mice
- Poster presentation “Syngeneic bone metastasis models for testing efficacy of novel therapies
- Poster presentation “Human Immune System Engrafted Mouse Models of Triple-Negative and Triple-Positive Breast Cancer for Preclinical Validation of Novel Immuno-Oncology Therapies
In the seminar “Example Studies in Immunodeficient and Humanized Mouse Models and Considerations for Drug Development” Pharmatest will present bone metastasis models established in humanized mice.
Pharmatest welcomes everyone to attend the free seminar and networking event after it. You can find more information about the seminar and register in the following link: Oncology seminar registration (registration has closed).
March 11, 2019
Pharmatest Services attends Annual Meeting of American Association for Cancer Research (AACR) held in Atlanta, Georgia, USA on March 30 – April 3, 2019. Pharmatest attends the event with a booth (#4730) and is presenting 8 scientific presentations.
Pharmatest Services (Pharmatest) is a contract research organization that offers preclinical efficacy services for the pharmaceutical industry in the fields of oncology and skeletal diseases. The Annual Meeting of AACR is the leading scientific event in the field of cancer research globally.
This year in AACR Pharmatest presents the following 8 scientific presentations:
- Poster ID 2007: Validation of a preclinical model for bone metastatic triple negative breast cancer. Poster presentation on Monday April 1 at 1:00 PM – 5:00 PM by Justyna Zdrojewska, section 7, poster board 15. (Collaboration with Polyphor Ltd, Allschwil, Switzerland)
- Poster ID 2161: In vitro osteoblast assays for studying the effects of cancer therapeutics on bone biology. Poster presentation on Monday April 1 at 1:00 PM - 5:00 PM by Jenni Mäki-Jouppila, section 13, poster board 12.
- Poster ID 2814: Systemic and local syngeneic bone metastasis models for immuno-oncology drug development. Poster presentation Tuesday April 2 8:00 AM - 12:00 PM by Tiina Kähkönen, section 3, poster board 30. (Collaboration with Bayer AG, Berlin, Germany)
- Poster ID 3936: Efficacy of single agent radium-223 in the syngeneic MBT-2 bladder cancer bone growth model in mice. Poster presentation on Tuesday April 2 at 1:00 PM - 5:00 PM by Tiina Kähkönen, section 15, poster board 17. (Collaboration with Aurexel Life Sciences Ltd., Askainen, Finland; Vincit Oy, Turku, Finland and Bayer AG, Berlin, Germany)
- Poster ID 4588: Characterization of anti-CTLA-4 effects on tumor growth and immune microenvironment in a syngeneic CT26.WT colon carcinoma mouse model. Poster presentation on Wednesday April 3 8:00 AM - 12:00 PM by Jenni Mäki-Jouppila, section 4, poster board 12. (Collaboration with OracleBio, North Lanarkshire, Scotland, UK and BioSiteHisto, Tampere, Finland)
- Poster ID 4614: Establishment of a HER2 positive breast cancer bone metastasis model for validation of novel therapies. Poster presentation on Wednesday April 3 at 8:00 AM - 12:00 PM by Tiina Kähkönen, section 6, poster board 9. (Collaboration with Bayer AS, Oslo, Norway)
- Poster ID 4616: Establishment of a metastatic orthotopic model of pancreatic ductal adenocarcinoma (PDAC) for drug development. Poster presentation on Wednesday April 3 at 8:00 AM - 12:00 by Justyna Zdrojewska, section 6, poster board 11. (Collaboration with Pharmaxis, New South Wales, Australia)
- Poster ID 4850: The relevance of using proper preclinical models when developing therapeutics for localized or bone metastatic prostate cancer. Poster presentation on Wednesday April 3 at 8:00 AM – 12:00 PM by Jenni Bernoulli, section 15, poster board 8.
Pharmatest welcomes everyone to visit our posters and booth #4730 in AACR. If you would like to meet our representatives during the event, contact us here.
January 11, 2019
Pharmatest has announced the list of events where Pharmatest representatives will attend during 2019. The first events include immuno-oncology seminars in San Francisco on January 22 and San Diego on January 28, and Tumor Models event organized by Hanson Wade in San Francisco on January 23 – 24.
Pharmatest Services is a CRO that offers preclinical efficacy services in the fields of oncology and skeletal diseases. In oncology Pharmatest has been a pioneer in offering bone metastasis models since 2005, and is today the global leader in the field.
The list of events where Pharmatest representatives will attend during 2019 can be found here. The list includes scientific meetings and conventions, and the previously announced immuno-oncology seminars organized by Pharmatest together with our partners.
The first events include immuno-oncology seminars in San Francisco on January 22 and San Diego on January 28, and Tumor Models event organized by Hanson Wade in San Francisco on January 23 – 24. In the Tumor Models event Pharmatest has a booth and the following scientific presentations:
- Oral presentation on January 23 at 4.15 pm titled “Importance of the microenvironment in evaluating IO therapy response – case studies from bone metastasis models in humanized mice”.
- Two poster presentations titled:
- “Characterization of tumor-infiltrating immune cells and the efficacy of pembrolizumab in preclinical models of primary and bone metastatic triple-negative breast cancer”.
- “Systemic and local syngeneic bone metastasis models for immuno-oncology drug development”.
If you would like to schedule a meeting with our representatives during the events, click here.
December 5, 2018
Pharmatest Services arranges an immuno-oncology seminar series about humanized mouse models during 2019. The first seminars are part of the Biocom seminar series and they will be held in San Francisco on January 22 and in San Diego on January 28.
A large amount of immunotherapies are currently under development, and reliable preclinical models are needed to confirm their efficacy before entering clinical trials. The Pharmatest 2019 seminar series includes speakers from many of our partners and covers extensively the utility of humanized mouse models in oncology.
Pharmatest has been the leading expert and provider of bone metastasis models for over 10 years. In the seminars Pharmatest will present humanized mouse models of bone metastasis, showcasing how immunotherapies can affect differentially tumor growth in metastatic sites than in primary tumors, demonstrating the importance of confirming compound efficacy in relevant metastasis models.
The following five seminars have been confirmed for 2019:
- San Francisco, CA, USA, January 22 with Champions Oncology
- San Diego, CA, USA, January 28 with Taconic Biosciences
- Berlin, Germany, March 19 with EPO Berlin-Buch
- London, UK, May 23 with Valirx Plc
- Cambridge, MA, USA, September 19 with Taconic Biosciences
The first seminars in San Francisco and San Diego, titled “Pre-Clinical Efficacy Models for Immuno-Oncology Studies in Humanized Mice”, are part of the Biocom seminar series. You can register to the seminars from the following links:
- Biocom seminar San Francisco Jan 22 (registration has closed)
- Biocom seminar San Diego Jan 28 (registration has closed)
Pharmatest welcomes everyone to join the seminars to learn more about the use of humanized mouse models in preclinical efficacy studies in oncology, and to discuss with the expert speakers.
September 19, 2018
Pharmatest Services attends ASBMR Annual Meeting in Montreal, Canada on September 28 – October 1, 2018. In ASBMR Pharmatest launches two new services, a preclinical mouse model of osteogenesis imperfecta and clinical bone marker measurement services.
Pharmatest Services (Pharmatest) is a CRO that offers preclinical efficacy services in the fields of oncology and skeletal diseases. In skeletal diseases Pharmatest offers bone cell culture models and animal models of osteoporosis and osteoarthritis.
Pharmatest now widens its portfolio of preclinical efficacy models in skeletal diseases by launching a mouse model of osteogenesis imperfecta (OI). The model utilizes heterozygous (+/G610C) male mice that exhibit a variable form of OI (type IV).
Jussi Halleen, CEO of Pharmatest comments: “The OI model that we are now launching is our first model of rare bone diseases, and it strengthens our position as a CRO offering preclinical efficacy models in skeletal diseases.”
Pharmatest has strong expertise in performing bone turnover marker measurements in its preclinical efficacy models. Pharmatest now launches clinical bone marker measurements that are performed using the iSYS automated platform of Immunodiagnostic Systems Plc (IDS).
Katja Fagerlund, Research Director in the bone marker unit of Pharmatest says: “We have a long history in collaborating with IDS and offering bone turnover marker measurements in our preclinical studies. We are now very excited to start offering also clinical bone marker measurements using the IDS-iSYS automated platform.”
September 17, 2018
Pharmatest Services attends Annual Meeting of The American Society for Bone and Mineral Research (ASBMR) that will be held in Montreal, Canada on September 28 – October 1, 2018. Pharmatest attends the event with a booth (#217) and has 4 scientific presentations.
Pharmatest Services is a contract research organization that offers preclinical efficacy services for the pharmaceutical industry in the fields of oncology and skeletal diseases. ASBMR Annual Meeting is the leading scientific event in the field of bone research globally.
This year Pharmatest attends ASBMR with the following four scientific presentations:
- Bone metastatic growth was not inhibited by anti-PD-1 blockage in a humanized mouse model of triple-negative breast cancer – difference in responses between primary and bone metastatic tumors (collaboration with Taconic Biosciences, USA). Poster presentation LB SAT-1164 by Tiina Kähkönen on September 29, 12:30 pm - 2:30 pm at ASBMR Discovery Hall – Hall 220 B-E.
- Intra-Articular Monosodium Iodoacetate Induced Knee Osteoarthritis: Effects on Bone as Measured by Micro-Computed Tomography in Rats. Poster presentation SAT-0986 by Jukka Vääräniemi on September 29 from 12:30 pm – 2:30 pm at ASBMR Discovery Hall – Room 220 B-E. This poster will also be presented at ASBMR Symposium on Skeletal Contributions to Joint Degeneration and Osteoarthritis (#P-49) at room 513 of the Palais des Congres on September 27, 2018 from 8:00 am – 6:00pm.
- Analgesic Effects of Morphine on Knee Osteoarthritis Induced by Intra-Articular Monosodium Iodoacetate in Rats. Poster presentation SUN-0995 by Jukka Morko on Sunday, September 30 from 12:30 pm – 2:30 pm at ASBMR Discovery Hall – Room 220 B-E. This poster will also be presented at ASBMR Symposium on Skeletal Contributions to Joint Degeneration and Osteoarthritis (#P-44) at room 513 of the Palais des Congres on September 27, 2018 from 8:00 am – 6:00pm.
- The effects of castration on prostate cancer tumor growth in bone (collaboration with Bayer AG, Berlin, Germany). Poster presentation MON-0215 by Tiina Kähkönen on October 1, 12:00 pm-02:00 pm at ASBMR Discovery Hall - Exhibit Hall 220 B-E.
Pharmatest welcomes everyone to visit our posters and booth #217 in the event. If you would like to schedule a meeting with our representatives during the ASBMR meeting click here.
May 24, 2018
June 15, 2018 marks the 20th anniversary of Pharmatest Services. We will be celebrating this important milestone by hosting a celebration Symposium on this same day at the PharmaCity Building in Turku, Itäinen Pitkäkatu 4, 20520 Turku, Finland.
We are proud to announce our guest speakers including the Rector of the University of Turku Kalervo Väänänen who was one of the founders of Pharmatest. Dr. Risto Lammintausta, CEO of Forendo Pharma has a long history with Pharmatest as customer and previous Board Member, and over 30 years of drug development experience.
Symposium schedule:
- 13.00: Opening words - Jenni Bernoulli, COO, Pharmatest Services
- 13.05: Jussi Halleen, CEO, Pharmatest Services – History of Pharmatest
- 13.20: Kalervo Väänänen, Rector, University of Turku - Research – Innovation – Entrepreneurship
- 13.40: Risto Lammintausta, CEO, Forendo Pharma - Drug discovery and development in the new business network
- 14.00: Andrew Heiniluoma, Business Development Director, Pharmatest Services LLC - Pharmatest in USA
- 14.15: Tiina Kähkönen, Research Director, Pharmatest Services - Humanized mouse models of bone metastasis
- 14.45: Closing words - Jenni Bernoulli
March 21, 2018
Pharmatest Services attends Annual Meeting of American Association for Cancer Research (AACR) held in Chicago, Illinois, USA on April 14 – 18, 2018. Pharmatest attends the event with a booth (#3640) and is presenting 8 scientific presentations.
Pharmatest Services (Pharmatest) is a contract research organization that offers preclinical efficacy services for the pharmaceutical industry in the fields of oncology and skeletal diseases. The Annual Meeting of AACR is the leading scientific event in the field of cancer research globally.
This year in AACR Pharmatest presents the following 8 scientific presentations:
- Poster ID 709: Anti-PD-1 therapy reduces bone lesion growth in a novel syngeneic bladder cancer bone metastasis model. Poster presentation on Sunday April 15 at 1:00 PM - 5:00 PM by Tiina Kähkönen, section 33, poster board 6. (Collaboration with Bayer AG, Berlin, Germany).
- Poster ID 838: Synergistic in vivo activity of the ATR inhibitor BAY 1895344 in combination with the targeted alpha therapy radium-223 dichloride in a preclinical tumor model mimicking bone metastatic castration-resistant prostate cancer (mCRPC). Poster presentation on Sunday April 15 at 1:00 pm – 5:00 pm by Mari Suominen, Section 39, poster board 1. (Collaboration with Bayer AG, Berlin, Germany).
- Poster ID 1158: Phenotypic screening using AMIDA identifies different drug responses in breast and prostate cancer cell lines in an organotypic cell culture model. Poster presentation on Monday April 16 at 8:00 AM - 12:00 PM by Katja Fagerlund, section 6, poster board 15. (Collaboration with University of Turku, Turku, Finland).
- Poster ID 1677: Differential efficacy of PD-1 targeted immunomodulation in preclinical models of primary and bone metastatic triple-negative breast cancer. Poster presentation on Monday April 16 at 8:00 AM - 12:00 PM by Tiina Kähkönen, section 31, poster board 2. (Collaboration with Taconic Biosciences, Rensselaer, NY and BioSiteHisto Ltd, Tampere, Finland).
- Poster ID 1738: PD-1/PD-L1 expression and tumor-infiltrating immune cells in triple-negative breast cancer: Characterization of preclinical primary tumor and bone metastasis models in humanized mice. Poster presentation on Monday April 16 at 8:00 AM - 12:00 PM by Jenni Bernoulli from Pharmatest and Philip Dube from Taconic Biosciences, section 33, poster board 3. (Collaboration with Taconic Biosciences, Rensselaer, NY and BioSiteHisto Ltd, Tampere, Finland).
- Poster ID 1162: Castration-resistant prostate cancer bone metastasis model to assess new therapeutics. Poster presentation on Monday April 16 at 8:00 AM - 12:00 PM by Mari Suominen, section 6, poster board 19. (Collaboration with Bayer AG, Berlin, Germany).
- Poster ID 2684: Drug sensitivity profiling of BT-474 breast cancer cell line for identification of novel therapies targeting HER2-positive breast cancer. Poster presentation on Monday April 16 at 1:00 PM - 5:00 PM by Jenni Mäki-Jouppila, section 30, poster board 24. (Collaboration with Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland).
- Poster ID 3859: Hormone receptor and HER2/HER3 expression in preclinical breast cancer models of primary tumor and bone metastasis. Poster presentation on Tuesday April 17 at 8:00 AM - 12:00 PM by Jenni Bernoulli, section 36, poster board 2. (Collaboration with Taconic Biosciences, Rensselaer, NY and BioSiteHisto Ltd, Tampere, Finland).
Pharmatest welcomes everyone to visit our booth #3640 in AACR. If you would like to meet our representatives during the event, click here.
Find us
HEADQUARTERS
Research laboratories
Pharmatest Services
Itäinen Pitkäkatu 4 C, 5th floor
FI-20520 Turku
FINLAND
Tel. +358 2 278 4700
